-
1
-
-
33847126689
-
Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation
-
Asselin-Labat ML, Sutherland KD, Barker H, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 2007;9:201-209.
-
(2007)
Nat Cell Biol
, vol.9
, pp. 201-209
-
-
Asselin-Labat, M.L.1
Sutherland, K.D.2
Barker, H.3
-
2
-
-
73949087506
-
GATA3 in development and cancer differentiation: Cells GATA have it!
-
Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol. 2010;222:42-49.
-
(2010)
J Cell Physiol
, vol.222
, pp. 42-49
-
-
Chou, J.1
Provot, S.2
Werb, Z.3
-
3
-
-
41549107036
-
GATA-3 and the regulation of the mammary luminal cell fate
-
Kouros-Mehr H, Kim JW, Bechis SK, et al. GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol. 2008;20:164-170.
-
(2008)
Curr Opin Cell Biol
, vol.20
, pp. 164-170
-
-
Kouros-Mehr, H.1
Kim, J.W.2
Bechis, S.K.3
-
4
-
-
79960036820
-
GATA transcription factors and cancer
-
Zheng R, Blobel GA. GATA transcription factors and cancer. Genes Cancer. 2010;1:1178-1188.
-
(2010)
Genes Cancer.
, vol.1
, pp. 1178-1188
-
-
Zheng, R.1
Blobel, G.A.2
-
5
-
-
62849083671
-
Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations
-
Esheba GE, Longacre TA, Atkins KA, et al. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations. Am J Surg Pathol. 2009;33:347-353.
-
(2009)
Am J Surg Pathol
, vol.33
, pp. 347-353
-
-
Esheba, G.E.1
Longacre, T.A.2
Atkins, K.A.3
-
6
-
-
34247630071
-
Placental S100 (S100P) and GATA3: Markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray
-
Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-680.
-
(2007)
Am J Surg Pathol
, vol.31
, pp. 673-680
-
-
Higgins, J.P.1
Kaygusuz, G.2
Wang, L.3
-
7
-
-
33749018789
-
Pleomorphic giant cell adenocarcinoma of the prostate: Report of 6 cases
-
Parwani AV, Herawi M, Epstein JI. Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. Am J Surg Pathol. 2006;30:1254-1259.
-
(2006)
Am J Surg Pathol
, vol.30
, pp. 1254-1259
-
-
Parwani, A.V.1
Herawi, M.2
Epstein, J.I.3
-
8
-
-
34547643155
-
Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma
-
Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31:1246-1255.
-
(2007)
Am J Surg Pathol
, vol.31
, pp. 1246-1255
-
-
Chuang, A.Y.1
Demarzo, A.M.2
Veltri, R.W.3
-
9
-
-
0031723377
-
Thrombomodulin expression in transitional cell carcinoma
-
Ordonez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol. 1998;110:385-390.
-
(1998)
Am J Clin Pathol
, vol.110
, pp. 385-390
-
-
Ordonez, N.G.1
-
10
-
-
0037215340
-
Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytoker-atin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas
-
Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytoker-atin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27:1-10.
-
(2003)
Am J Surg Pathol
, vol.27
, pp. 1-10
-
-
Parker, D.C.1
Folpe, A.L.2
Bell, J.3
-
11
-
-
0037324298
-
High molecular weight cytokeratin antibody (clone 34betaE12): A sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer
-
Varma M, Morgan M, Amin MB, et al. High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer. Histopathology. 2003;42:167-172.
-
(2003)
Histopathology
, vol.42
, pp. 167-172
-
-
Varma, M.1
Morgan, M.2
Amin, M.B.3
-
12
-
-
0035184548
-
Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas
-
Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116:823-830.
-
(2001)
Am J Clin Pathol
, vol.116
, pp. 823-830
-
-
Kaufmann, O.1
Fietze, E.2
Mengs, J.3
-
13
-
-
33846606406
-
Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas
-
Owens SR, Greenson JK. Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas. Am J Surg Pathol. 2007;31:285-290.
-
(2007)
Am J Surg Pathol
, vol.31
, pp. 285-290
-
-
Owens, S.R.1
Greenson, J.K.2
-
14
-
-
0034986554
-
Histologic and immunophe-notypic classification of cervical carcinomas by expression of the p53 homologue p63: A study of 250 cases
-
Wang TY, Chen BF, Yang YC, et al. Histologic and immunophe-notypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol. 2001;32:479-486.
-
(2001)
Hum Pathol.
, vol.32
, pp. 479-486
-
-
Wang, T.Y.1
Chen, B.F.2
Yang, Y.C.3
-
15
-
-
0036724297
-
Can basal cells be seen in adenocarcinoma of the prostate?: An immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody
-
Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol. 2002;26:1151-1160.
-
(2002)
Am J Surg Pathol
, vol.26
, pp. 1151-1160
-
-
Oliai, B.R.1
Kahane, H.2
Epstein, J.I.3
-
16
-
-
0034424842
-
Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas
-
Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113:683-687.
-
(2000)
Am J Clin Pathol.
, vol.113
, pp. 683-687
-
-
Kaufmann, O.1
Volmerig, J.2
Dietel, M.3
-
17
-
-
0345189361
-
Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder
-
Koga F, Kawakami S, Fujii Y, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003;9:5501-5507.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 5501-5507
-
-
Koga, F.1
Kawakami, S.2
Fujii, Y.3
-
18
-
-
79954531419
-
Different immunohis-tochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer
-
Gaisa NT, Braunschweig T, Reimer N, et al. Different immunohis-tochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer. Virchows Arch. 2011;458:301-312.
-
(2011)
Virchows Arch
, vol.458
, pp. 301-312
-
-
Gaisa, N.T.1
Braunschweig, T.2
Reimer, N.3
-
19
-
-
48349083444
-
Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer
-
Matsumoto K, Satoh T, Irie A, et al. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology. 2008;72:444-449.
-
(2008)
Urology
, vol.72
, pp. 444-449
-
-
Matsumoto, K.1
Satoh, T.2
Irie, A.3
|